| Literature DB >> 22428053 |
Jayendra Shankar1, Rachel G Walker, Deborah Ward, Malcolm J Horsburgh.
Abstract
Analysis of the culture supernatant exoproteins produced by two PFGE clusters of high-level gentamicin and ciprofloxacin-resistant clinical isolates of Enterococcus faecalis from the UK and Ireland revealed two distinct protein profiles. This grouping distinguished OG1RF and GelE metalloprotease-expressing isolates from JH2-2 and other GelE-negative isolates. The integrity of the fsrABDC operon was found to determine the exoproteome composition, since an fsrB mutant of strain OG1RF appeared very similar to that of strain JH2-2, and complementation of the latter with the fsrABDC operon produced an OG1RF-like exoproteome. The proteins present in the supernatant fraction of OG1RF were separated using 2D gels and identified by mass spectrometry and comprised many mass and pI variants of the GelE and SprE proteases. In addition cell wall synthesis and cell division proteins were identified. An OG1RF fsrB mutant had a distinct exoprotein fraction with an absence of the Fsr-regulated proteases and was characterised by general stress and glycolytic proteins. The exoproteome of the OG1RF fsrB mutant resembles that of a divIVA mutant of E. faecalis, suggestive of a stress phenotype.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22428053 PMCID: PMC3299793 DOI: 10.1371/journal.pone.0033450
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
E. faecalis strains used in this study.
|
| Alternative ID | Characteristics | Source |
| OG1RF | Wild type Rif r/Fusr |
| |
| JH2-2 | Wild type Rif r/Fusr naturally occurring |
| |
| OG1RF | TX5264 | In-frame deletion of |
|
| OG1RF | TX5266 |
|
|
| OG1RF | TX5245 |
|
|
| JH2-2 pTEX5249 | LIV305 |
| This study |
| V583 | Vanr |
| |
| EC23, EC117, EC95, EC207, EC238 | PFGE cluster 1 BSAC Bacteraemia Resistance Surveillance Programme (UK & Ireland) |
| |
| EC126, EC137, EC36, EC127, EC216 | PFGE cluster 2 BSAC Bacteraemia Resistance Surveillance Programme (UK & Ireland) |
| |
| 402,463,486,487, 488,489,499 (/96/NIPH) | Clinical isolates (Poland) |
| |
| IS19-IS48 | MLST-typed clinical isolates(Spain) |
|
Figure 1Exoproteins from E. faecalis strains OG1RF and JH2-2 and clinical isolates from separate PFGE clusters.
Stationary phase (8 h) culture supernatant from (A) strains OG1RF, JH2-2, PFGE cluster 1 strains EC23, EC117, EC95, EC207, EC238. (B) PFGE cluster 2 strains EC126, EC137, EC36, EC127, EC216. (C) strains V583, HH22, TX0104. GelE (G) and SprE (S) were identified by mass spectrometry. Molecular mass markers are indicated (kDa).
Figure 2Role of fsrB and gelE in modulating stationary phase (8 h) culture supernatant exoproteins.
E. faecalis strains OG1RF and isogenic mutants OG1RF gelE, OG1RF fsrB and OG1RF fsrB pTEX5249. Molecular mass markers are indicated (kDa).
Figure 3Complementation of Fsr function in strain JH2-2.
Stationary phase culture supernatant of strains OG1RF, JH2-2 and LIV643 (JH2-2 pTEX5249). Molecular mass markers are indicated (kDa).
Figure 4Temporal expression of E. faecalis OG1RF exoproteins.
Culture supernatant was sampled after early exponential (3 h), mid-exponential (5 h), stationary (8 h) and overnight growth (14 h). Molecular mass markers are indicated (kDa). Arrowheads indicate the 9 most prominent exoprotein bands.
Figure 5Stationary phase (8 h) exoproteins of E. faecalis OG1RF separated by 2D SDS-PAGE.
Arrowheads indicate spots to which an identity was assigned after MALDI-TOF analysis. The identified protein spots are listed in Table 2. Molecular mass markers are shown to the left (kDa). A representative image is shown.
Identification of exoproteins of E. faecalis OG1RF.
| Spot | Protein description (Gene) | Calculated mass (kDa)/pI | Peptides matched | Coverage (%) |
| 1 | GTP-binding protein LepA (EF_2352) | 68.27/4.99 | 10/28 | 20 |
| 2 | D-alanine–D-lactate ligase (EF_2294) | 21.24/4.7 | 6/31 | 52 |
| 3 | GTP-binding protein LepA (EF_2352) | 68.27/4.99 | 5/11 | 16 |
| 4 | DNA primase (EF_1521) | 73.01/5.12 | 6/20 | 19 |
| 5 | DNA polymerase III subunit alpha (EF_1044) | 31.35/4.96 | 5/17 | 35 |
| 6 | Transcriptional regulator, Cro/CI family (EF_2508) | 20.92/5.83 | 4/18 | 34 |
| 7 | VanXYG2; D-alanyl-D-alanine carboxypeptidase (Q30BF0_ENTFA) | 29.43/5.21 | 9/93 | 55 |
| 8 | Acetyltransferase, GNAT family (EF_1296) | 21.98/5.48 | 4/18 | 44 |
| 9 | Alpha-glycerophosphate oxidase (EF_1928) | 67.60/4.94 | 5/10 | 16 |
| 10 | Glycosyl hydrolase, family 20 (EF_0114) | 94.12/4.96 | 11/21 | 18 |
| 11 | Lipoteichoic acid synthase, LtaS (EF_1264) | 79.96/6.2 | 8/32 | 21 |
| 12 | Hypothetical protein (EF_1995) | 12.32/4.29 | 6/27 | 60 |
| 13 | LtaS (EF_1264) | 79.96/6.2 | 8/27 | 19 |
| 14 | Endo-beta-N-acetylglucosaminidase (EF_2863) | 34.54/5.96 | 7/29 | 26 |
| 15 | Serine protease, SprE (EF_1817) | 31.04/5.54 | 16/105 | 42 |
| 16 | Serine protease, SprE (EF_1817) | 31.04/5.54 | 14/56 | 39 |
| 17 | Septation ring formation regulator EzrA (EF_0370) | 68.11/4.75 | 8/27 | 24 |
| 18 | Serine protease, SprE (EF_1817) | 31.04/5.54 | 9/31 | 38 |
| 19 | Serine protease, SprE (EF_1817) | 31.04/5.54 | 5/19 | 25 |
| 20 | Serine protease, SprE (EF_1817) | 31.04/5.54 | 15/82 | 57 |
| 21 | Zn-Metalloprotease, GelE (EF_1818) | 55.34/4.99 | 10/33 | 32 |
| 22 | GelE (EF_1818) | 55.34/4.99 | 5/13 | 15 |
| 23 | Transcriptional regulator, TetR family (EF_1531) | 20.70/8.63 | 4/21 | 48 |
| 24 | GelE (EF_1818) | 55.34/4.99 | 6/16 | 14 |
| 25 | D-alanyl-D-alanine dipeptidase (EF_2293) | 23.20/5.8 | 4/16 | 26 |
| 26 | Zn-Metalloprotease, GelE (EF_1818) | 55.34/4.99 | 6/13 | 16 |
| 27 | Zn-Metalloprotease, GelE (EF_1818) | 55.34/4.99 | 6/18 | 16 |
| 28 | Zn-Metalloprotease, GelE (EF_1818) | 55.34/4.99 | 7/16 | 19 |
| 29 | Zn-Metalloprotease, GelE (EF_1818) | 55.34/4.99 | 10/34 | 32 |
| 30 | Serine protease, SprE (EF_1817) | 31.04/5.54 | 12/71 | 50 |
| 31 | Zn-Metalloprotease, GelE (EF_1818) | 55.34/4.99 | 7/21 | 19 |
| 32 | Zn-Metalloprotease, GelE (EF_1818) | 55.34/4.99 | 8/16 | 23 |
| 33 | Hypothetical protein (EF_0841) | 39.46/5.61 | 6/58 | 27 |
| 34 | DNA replication protein, putative (EF_1279) | 29.74/6.19 | 5/17 | 31 |
| 35 | Serine protease, SprE (EF_1817) | 31.04/5.54 | 10/57 | 39 |
| 36 | Septation ring formation regulator EzrA (EF_0370) | 68.28/4.75 | 9/20 | 31 |
| 37 | Ribosomal protein L11 RplK (EF_2719) | 14.68/9.52 | 5/23 | 47 |
| 39 | Hypothetical protein (EF_0486) | 8.62/6.23 | 4/26 | 66 |
| 40 | Hypothetical protein (EF_2308) | 3.23/5.91 | 2/15 | 84 |
| 41 | Transcriptional regulator, Cro/CI family (EF_2508) | 20.92/5.83 | 5/27 | 37 |
| 42 | Hypothetical protein (EF_2843) | 8.41/4.6 | 4/21 | 56 |
| 43 | Hypothetical protein (EF_1926) | 20.78/9.32 | 5/25 | 34 |
| 44 | ATP synthase F0, AtpE (EF_2613) | 7.61/6.07 | 4/20 | 63 |
Spot numbers correspond to those in Figure 5.
Figure 6Exoproteins of E. faecalis strain TX5266 (OG1RF fsrB) following overnight growth separated by 2D SDS-PAGE.
Arrowheads indicate spots to which an identity was assigned after MALDI-TOF analysis. Identified protein spots are listed in Table 3. Molecular mass markers are shown (kDa). A representative image is shown.
Identification of exoproteins of E. faecalis strain TX5266 (OG1RF fsrB).
| Spot | Protein description (Gene) | Calculated mass (kDa)/pI | Peptides matched | Coverage (%) |
| 1a | RNA polymerase omega subunit, RpoZ (EF_3126) | 11.53/5.36 | 6/35 | 51 |
| 2a | 30S ribosomal protein S6, RpsF (EF_0007) | 11.59/5.01 | 7/11 | 48 |
| 3a | Dps Family protein (EF_3233) | 17.93/4.56 | 6/11 | 33 |
| 4a | Fumarate reductase subunit (EF_2556) | 53.83/5.26 | 12/35 | 25 |
| 5a | Alkyl hydroperoxide reductase, AhpC (EF_2739) | 21.3/4.5 | 16/22 | 43 |
| 6a | N-acetylmuramoyl-L-alanine amidase (EF_1823) | 30.32/4.89 | 3/4 | 16 |
| 7a | Hypothetical protein (EF_1470) | 14.62/5.61 | 5/26 | 38 |
| 8a | ABC transporter, ATP-binding protein (EF_2394) | 28.40/4.73 | 9/13 | 37 |
| 9a | Glycine betaine/carnitine/choline ABC transporter (EF_0863) | 34.72/5.14 | 16/21 | 41 |
| 10a | Fructose-bisphosphate aldolase class II, Fba (EF_1167) | 31.02/4.86 | 7/14 | 26 |
| 11a | Adenylate kinase (EF_0228) | 24.25/5.05 | 9/15 | 36 |
| 12a | Phosphoglycerate mutase I, GpmA (EF_0195) | 26.05/5.09 | 11/21 | 34 |
| 13a | Endo-beta-N-acetylglucosaminidase (EF_2863) | 35.54/5.96 | 6/10 | 25 |
| 14a | Tail protein, putative (EF_1829) | 37.97/5.27 | 8/21 | 27 |
| 15a | Hypothetical protein (EF_0375) | 35.43/7.07 | 9/19 | 28 |
| 16a | Endolysin. Ply-1 (EF_1293) | 40.14/5.70 | 11./1 | 30 |
| 17a | Catabolite control protein A, CcpA (EF_1741) | 36.19/5.27 | 13/14 | 30 |
| 18a | Chitinase, family 2 (EF_0361) | 38.31/5.31 | 6/10 | 13 |
| 19a | Phosphotransacetylase Pta (EF_0949) | 35.59/4.97 | 7/19 | 30 |
| 20a | Translation elongation factor, Ts, Tsf (EF_2397) | 32.11/4.87 | 18/43 | 51 |
| 21a | L-lactate dehydrogenase Ldh (EF_0255) | 35.52/4.77 | 14/38 | 47 |
| 22a | Pyruvate dehydrogenase E1 component, PdhB (EF_1354) | 35.37/4.67 | 12/46 | 37 |
| 23a | Basic membrane protein family (EF_0177) | 37.78/4.88 | 8/15 | 21 |
| 24a | Basic membrane protein family (EF_0177) | 37.78/4.88 | 4/15 | 14 |
| 25a | Arginine deiminase, ArcB (EF_0105) | 38.13/5.02 | 19/28 | 46 |
| 26a | Pyruvate dehydrogenase complex E1 component, PdhA (EF_1353) | 41.35/5.25 | 8/12 | 24 |
| 27a | Glyceraldehyde 3-phosphate dehydrogenase, Gap-2 (EF_1353) | 35.92/5.03 | 7/17 | 24 |
| 28a | Acetate kinase, AckA (EF_1983) | 43.49/4.96 | 12/15 | 33 |
| 29a | Phosphoglycerate kinase, Pgk (EF1963) | 42.42/4.90 | 16/36 | 49 |
| 30a | Arginine deiminase, ArcB (EF_0105) | 38.13/5.02 | 20/26 | 41 |
| 31a | Enolase, Eno (EF_1961) | 46.48/4.56 | 12/34 | 36 |
| 32a | Lipoteichoic acid synthase, LtaS (EF_1264) | 79.96/6.2 | 12/24 | 15 |
| 33a | Lipoteichoic acid synthase, LtaS (EF_1264) | 79.96/6.2 | 19/36 | 30 |
| 34a | ErfK/YbiS/YcfS/YnhG family protein, putative (EF_2860) | 52.77/6.74 | 20/38 | 35 |
| 35a | DnaK (EF_1308) | 65.54/4.59 | 12/20 | 23 |
| 36a | GroEL (EF_2633) | 55.41/4.66 | 18/24 | 28 |
| 37a | Putative ATPase, CbiA (Q9AL20) | 34.43/5.17 | 7/25 | 25 |
| 38a | Glutamate dehydrogenase, GdhA (EF1415) | 49.62/5.42 | 11/33 | 29 |
Spot numbers correspond to those in Figure 6.